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Psychotropic drugs are routinely prescribed in the 
treatment of psychosis. In the twenty years since their 
first clinical application their e:ffectiveness in supressing 
psychotic symptoms and relieving acute subjective distress 
has been well documented (Klein and Davis, 1969a; Klein and 
Lehmann, 1965). In several well-controlled studies comparing 
the effects of the major psychotropics with those of placebos, 
the former were found to be significantly more effective than 
the latter in preventing the reappearance of psychotic symp-
toms (Casey, Hollister, Klett, Lasky and Caffey, 1961; Klein 
and Davis, l969a; Davis, 1965; Englehardt, Rosen, Freedman 
and Margolis, 1967). Once an effective medication regimen 
has been developed and stabilized, the psychotic patient may 
benefit more fully from other forms of therapy and may be 
able to move from the hospital into the community. The 
dramatic decline in state hospital inpatient populations 
during the last two decades is often attributed in large 
part to the wide use and the effectiveness of psychotropic 
drugs (Klein and Davis, 1973; Hoffman, Moore and O'Dea, 
1974). However, an extensive review of the literature by 
Klein and Davis (l969b) provides strong support for the 
position that continuous, carefully-monitored, lung-term 
chemotherapy is essential to tbe prevention of the rehospit-
alization of many psychiatric outpatients. 
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A factor which may limit the effectiveness of any 
medication regimen is the degree to which the patient com-
plies with the prescribing physician's instructions as to 
how the drug should be taken. The patient may (a) take 
more or less of the prescribed drug than directed; (b) 
take it for the wrong reason; or (c) take it at the wrong 
time. Extensive research has found high noncompliance rates 
in many patient populations and with many types of drugs, 
but the noncompliance rates found in psychiatric outpatient 
populations are among the highest. An important review of 
the literature by Marston (1970) cites a study by Lipman, 
Rickels, Uhlenhuth, Park and Fisher (1965) which estimated 
that 42% of the psychiatric outpatient sample studied was 
noncompliant. Park and Lipman (1964) found a noncompliance 
rate of 51% for a sample from the same population. Similarly, 
Parkes, Brown and Monck (1962) found a rate of 44%, and 
Willcox, Gillan and Hare (1965) found one of 48%. None of 
these figures was intended to represent the noncompliance rate 
for the entire psychiatric outpatient population; however, it 
is clear that the failure to take mainten~nce psychotropic 
medications as directed is a serious problem which signifi-
cantly limits their effectiveness, and may be a precipitating . 
factor in many rehospitalizations. 
Attempts to decrease noncompliance have met with 
mixed- succ@ss. Citing studies __ by Malahy_(l9B_6}, who found 
a significant correlation between the number of medications 
prescribed and noncompliance, and Porter (1969), who found 
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that a once-daily dose maintained compliance better than a 
divided regimen, Blackwell (1972) suggests that the complex-
ity of the regimen may have a marked eJfect of noncompliance. 
Further, Blackwell (1972) cites two studies (Luntz and 
Austin, 1960; Porter, 1969) which demonstrate that the num-
ber of weeks or months drugs must be taken is negatively cor-
related with compliance. In a later study Blackwell (1973) 
suggests that the regimen be prescribed in such a way as 
to minimize its interference with the patient's normal daily 
routine with attention to meal times, daily activities, and 
sleeping hours. Since psychotropic medication regimens are 
often necessarily complex and of long duration, the above 
measures are not often appropriate. 
Both the prescribing physician and the dispensing 
pharmacist can attempt to explain the nature and purpose of 
each medication to the patient. Linkewich, Catalano and 
Flack (1974) found that imparting this information to the 
patient, along with other procedures, significantly increased 
compliance. The regimen studied by those experimenters, how-
ever, involved only one medication and a short duration, and 
the applicability of their procedures to more complex regi-
mens must be determined by further study. 
Unit dose packaging of drugs has been assumed to 
increase the outpatient's accuracy in self-medication. 
Specialized medication packaging systems were developed in 
the middle 1950's to simplify inventory procedures in 
I 
hospitals and clinics. They came to be known commonly as 
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unit-dose delivery systems, and as their advantages became 
manifest they were adapted to allow their use by outpatients. 
The most common examples of unit-dose ~ackaging for out-
patient use are found with birth control pills. There is 
little data, however, to support the assumption that unit-
dose packaged medications are taken with more accuracy 
than vial-packaged medications. 
Azrin and Powell (1969) developed a mechanism which 
would sound a tone at the present time, cuing the user 
to turn a knob on the mechanism which would terminate the 
tone and eject a tablet. This device significantly re-
duced errors in medication-taking in six normal subjects. 
This study demonstrated the value of specialized packaging 
in reducing non-compliance, but its applicability is limited 
by its cost and the fact that it can accommodate only one 
prescription when many patients, especially psychiatric out-
patients, are prescribed more complex regimens. 
The lower cost and greater flexibility of unit-dose 
packaging systems give them the potential for wider applica-
tion. The analog study by Azrin and Powell (1969) demon-
strated the value of the facilitative-packaging approach to 
noncompliance, and Linkewich, et ~1. (1974) found that two 
types of unit-dose packaging systems were significantly more 
effective in maintaining compliance than when the same medi-
cations were delivered in vials. There is no data to date, 
however, on the application of unit...:dose-packagllig sys"tems 
to psychiatric outpatient populations. Moreover, the complex 
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regimens common in that population cannot be accommodated 
in the usual unit-dose systems. 
The effectiveness of packaging systems, such as 
those described, in reducing noncompliance is probably due 
to a facilitation of self-monitoring by the patient of his 
or her medication-taking behavior. Conceptualized in this 
way, the approaches to self-control developed within the 
framework of applied behavior analysis (Thoresen and Mahoney, 
1974) have particular and relevance to the problem of non-
compliance. Mahoney and Thoresen (1974) state that there is 
often a reactive effect of self-monitoring upon the fre-
quency of the behavior under observation, but that effect 
often fails to endure over time and must be maintained 
through the application of other procedures, such as posi-
tive reinforcement, 
In the treatment of other health-related problems, 
behavior analysis has been found to be an effective strategy 
(Berni and Fordyce, 1973; Katz and Zlutnick, 1975; Lachman, 
1972). Contingent positive reinforcement in particular 
is often a useful technique. Leitenberg, Agras, and 
Thompson (1968) used contingent verbal reinforcement (praise) 
to increase the number of mouthfuls of food taken and 
gains in weight achieved by two patients with diagnosis 
of anorexia nervosa. Fordyce, Flower, Lehmann, and Delateur 
(1968) found that contingent verbal reinforcement and rest 
-- -
were effec·tive in increasing patient compliance with 
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medical staff directives concerning exercise in three patients 
with chronic pain problems. 
In the present study, the effects of (a) unit-dose 
packaging to facilitate self-monitoring of medication-taking 
behavior and (b) positive verbal reinforcement to maintain 
the reactive effects of self-monitoring were evaluated in 
six psychiatric outpatients. 
METHOD 
Subjects 
Six subjects were obtained from a list of refer-
rals compiled by the staff of the Adult Outpatient Clinic 
of the San Joaquin County Mental Health Services. Author-
ization for the inclusion of County clients in this research 
was given in writing by the Deputy Director of the County 
Mental Health Services and verbally by the Director of 
Outpatient Services. Referrals were requested from each 
physician on the Adult Outpatient Clinic staff by circu-
lating a memo, having announcements made in the weekly 
staff meetings, and in personal meetings with three of 
the staff physicians. 
The following criteria were set to establish the 
appropriateness of each referral: (a) presence of non-
compliance or suspicion of same; (b) possession of a stable, 
local residence; (c) living with friends, relatives or 
alone and not in a residential care facility (in these 
facilities, the residents' medication intake is closely 
supervised and compliance rates are high as a result); (d) 
absence of PRN -- to be taken as needed -- or liquid medi-
cations in the prescribed regimens (noncompliance with PRN 
prescriptions is difficult to define or to detect, and liquids 
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could not be accommodated in the unit~dose packaging system 
used); (e) maintenance of a stable regimen by the prescrib-
ing physician with no changes expected during the length of 
the study. This last requirement was later found to be un-
necessary as several changes in dosage strength and schedule 
were accommodated during the treatment phases. 
Fifteen subjects were referred to the experimenter. 
Of these, two were not open cases of the clinic and had not 
been seen by a staff physician in at least six weeks; one 
had been prescribed one medication, which was to be taken 
only as needed (PRN); two were not discharged from the state 
hospital in time to be included; one had moved out of the 
state; two could not be located after two weeks of telephone 
calls and visits to their residences; one refused to par-
ticipate. Six subjects then remained on the referral list, 
and all of these served in the study. 
Subject 1 was a middle-income, single, caucasian 
female, employed sporadically, approximately 30 years old 
and living with her employed mother. Subject 2 was a mar-
ried, unemployed, lower-income black female, approximately 
35 years old, and living with her employed husband. Sub-
ject 3 was a married, unemployed, lower-income Chicano male, 
approximately 35 years of age, and living with his unemployed 
wife and four children. Subject 4 was a married, unemployed, 
middle-income, caucasian female, approximately 50 years of age 
and living with her employed husband. Subject 5 was a single, 
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unemployed, lower-income, black approximately 20 years old 
and living with his unemployed·mother and two younger sib-
lings. Subject 6 was a single, unemployed, lower-income, 
black female, approximately 40 years old, living with her 
three children, the oldest of whom also served as a sub-
ject in the study (Subject 5). The regimens for the six 
subjects included are summarized in Table l. 
Measure of Compliance 
The difficulties in the accurate assessment of medi-
cation compliance are cl.early described by Marston (1970). 
The major assessment techniques as cited by that writer in-
clude the drug or tracer excretion test, patient self-
report, direct observation, and the vial count. No single 
measure has been found to be optimally reliable and demons-
trably valid. The drug or tracer excretion tests, sup-
posedly the most valid, cannot be executed conveniently out-
side of the laboratory, and the slo\mess with which many 
medications are excreted renders those tests somewhat unre-
liable. Patient self-reports, as several investigators have 
found (e.g., Blackwell, 1972; Martston, 1970), significantly 
underestimate noncompliance rates. Direct observation, while 
useful in settings where close supervision is possible, is not 
applicable to adult outpatient populations. The vial count 
(or pill count) was, therefore, selected as the measure-
ment- technic}ue for- the presefft st-udy~ rt-s validity has heen 
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Table 1. Continued. 
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Medication Function 















































challenged by some (e.g., Blackwell, 1972) who cite the maxim 
that what has left the vial has not necessarily been through 
the patient, but other than the excretion tests, the other 
measurement techniques may suffer from the same shortcoming. 
Roth, Caron and Hsi (1970), however, found a correlation 
of .80 between the vial count and the drug tracer technique 
in measuring compliance, and Linkewich et al. (1974) suc-
cessfully used the unannounced vial count with the assump-
tion that its reliability, or lack thereof, would be equal 
for each of their control and treatment groups. 
An undercompliant subject who is able to anticipate 
a vial count may dispose of a number of uningested tablets 
or capsules prior to the count, seriously undermining its 
validity. Three elements of the procedures employed in the 
present study served to minimize the possibility of a sub-
ject's accurately anticipating a count: (a) all counts 
were unannounced; (b) counts were made at different times of 
day; and (c) counts were made in addition to those made for 
the purpose of gathering evaluative data. 
Vial counts made for the purpose of gathering data 
to evaluate the effectiveness of the treatment procedures 
employed are termed Data Counts and were made every three 
days. These were made at different times of the day but 
were always attempted between the same two prescribed medica-
tiori:..:taking times~ -T5.at is-, rr a subject-had be-en directed 
by the physician to take doses in the morning, at noon, 
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in the late afternoon, and in the evening (Q.I.D.), Data 
Counts were always attempted between the morning and noon 
dose times, or always between the noon and late afternoon 
times, or always between the late afternoon and evening 
dose times. Each Data Count for a subject, then, was based, 
whenever possible, upon the same number of medication-taking 
times, but did not occur at exactly the same time of day. 
The possibility remained, however, that the regular-
ity of the three-day schedule could become apparent to the 
subjects. An overcompliant subject could, then, omit one 
o~ more doses the evening before the third day in order to 
appear compliant, and an undercompliant subject could dis-
pose of several uningested tablets or capsules the evening 
before for the same reason. To reduce this possibility 
counts other than those made every third day were made on a 
varied schedule in order to induce the subject to think 
that he or she could expect a count at any time and on any 
day. These were simply termed Counts. The days and times 
of the occurrences of all Counts and Data Counts are shown 
in Appendix A. 
Variations in the schedules for both Counts and Data 
Counts were occasionally made necessary by the subject's 
not being available at the scheduled time. When this occurred, 
the experimenter repeatedly returned to the subject's resi-
dence until a count was made. 
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Unit-Dose Packaging System 
The Medi-DosejMedi-Cup System of Medi-Dose, Inc., of 
Sellersville, Pennsylvania, was used as the basis for the 
packaging system developed and evaluated by the experi-
menter in the present study. 1 The Medi-DosejMedi-Cup 
system provides an inexpensive way for the pharmacist to 
unit-dose package drugs extemporaneously. 
As this system was originally conceived, up to 
twenty-five single doses are individually sealed in a 
single sheet. On the reverse side of the sheet each medica-
tion cell is labeled with the name of the drug and the 
strength of the dose, as well as the serial number of the 
prescription. 
Individuals taking psychotropic medications, how-
ever, are often prescribed more than one of these drugs, 
and for the purposes of the present study, a packaging sys-
tern had to be developed which would accommodate daily 
regimens of between one and four different types of medica-
tions. Figures 1 through 6 show front views of the modifica-
tions made in the Medi-DosejMedi-Cup system by the 
experimenter to accomplish this for each of the six subjects 
included in the study. Each day's regimen was sealed into 
a single card with indications as to the date, day of the 
week, and time of day that each dose should be taken. The 
1The Medi-DosejMedi-Cup System conforms in all re-
spects to the guidelines for unit-dose packaging approved 
by the Board of Directors of the American Society of Hos-
pital Pharmacists on December 2, 1966 and revised on October 
22-27, 1970. 
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FIGURE l. Regimen Card containing one day's medications for 
Subject l. 
FIGURE 2. Regimen Card containing two days' medications for 
Subject 2. 
FIGURE 3. Regimen Card containing two days' medications 
for Subject 3. 
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FIGURE 4. Regimen Card containing two days' medications, one 
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FIGURE 5. Regimen Card containing one day's medications 
for Subject 5. 
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FIGURE G. Regimen Card containing one day's medications for 
Subject 6. 
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reverse side of each cell showed the name of the medication, 
the strength of the dose, and the serial number of the 
prescription. The strength of the dose was not necessarily 
the strength of the individual tablets or capsules contained 
in each cell; if the prescription was, for example, for 
two 10 mg. tablets of Librium to be taken four times daily, 
then the cell was marked with the total strength of the 
dose, in this case 20 mg. 
The daily unit-dose cards were placed into 5" x sn 
plastic file boxes (Sterling Plastics, Number 530) for the sub-
ject's convenience and to keep them in the proper sequence. 
On the underside of the lid of each container, a copy of the 
vial labels on each of the subject's prescriptions was attached. 
The State of California requires that all prescrip-
tion medications be dispensed in child-proof containers ex-
cept when the patient or physician waives that requirement. 
A copy of the informed consent agreement signed by all sub-
jects appears in Appendix B. It includes a provision for the 
waiver of the requirement for dispensing in child-proof con-
tainers. In the verbal instructions to the subjects at the 
time this consent agreement was signed, it was emphasized 
by the experimenter that the packaging to be used was not 
child-proof and that special precautions should be taken 
when children may be present. 
_ Federal regulations_ state that the packaging or re-
packaging of prescription drugs may be done only by physi-
cians, licensed pharmacists, or under the direct supervision 
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of one of these professionals. To comply with this require-
ment, the experimenter transported each subject's medications 
(with his or her written and verbal authorization) to a 
laboratory at the School of Pharmacy at the University of 
the Pacific where the experimenter packaged the drugs into 
the unit-dose form under the direct supervision of a 
licensed pharmacist. 
For Subjects 1, 2, and 3, the design employed was 
the single-case A-BC-B-A. For Subjects 4, 5, and 6, the de-
sign used was the single-case A-BC-B-BC-A. In both cases A 
represents the baseline and reversal phases during which the 
subject's compliance rate was measured but no attempt was 
Inade to modify it; BC represents the phases during which 
both unit-dose packaging and contingent verbal reinforcement 
were administered; and B represents the phases during which 
unit-dose packaging was administered alone. The more com-
plex design was employed in those cases in which a deteriora-
tion in performance was observed after the change from the 
BC phase to the B phase. A possible interpretation of this 
deterioration was that the initial effectiveness of the 
treatment procedures was due to a novelty effect, and the de-
terioration of performance was due to the loss of strength of 
this effect over time. To control for this, an additional BC 
phase was added. 
With the designs used, both the individual and 
additive effects of the two treatment variables could be 
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assessed, with a control, where necessary, for the loss of 
strength of a possible novelty effect. The applicability 
of single-case experimental designs to clinical research 
is described in depth by Barlow and Herson (1973). Briefly, 
the advantages of these designs lie in the fact that they 
allow the precise measurement of day-to-day changes in the 
performance of individual subjects, allowing the possible 
identification of environmental or subject variables. 
Since the present study represents the application of a 
new technique towards the solution of a common but dif-
ficult problem, these advantages were manifest. 
Procedure 
Every referred subject who met the criteria for 
inclusion was contacted by the experimenter by telephone 
and an appointment made for an initial interview at the 
subject's residence. At the interview, the nature and pur-
pose of the study was explained, using the information in 
Appendix C. All questions were fully answered by the 
experimenter. If the subject agreed to participate,his or 
her informed consent was obtained both verbally and in 
writing in conformance with the ethical standards of the 
American Psychological Association. Copies of the two con-
sent forms used appear in Appendix B. Each subject who 
agreed to participate signed a copy of each form for the 
experimenter's files and was given a copy of each for 
reference. 
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The counts for the phases in which the subjects' 
medications were packaged in vials were made using a count-
ing tray (Abbott Sanitary Counting Tray, Pat. No. 2530009) 
identical to those corr~only used by pharmacists to count 
the number of capsules or tablets required to fill a pre-
scription. The contents of each vial were poured on to the 
tray separately, counted, and returned to the vial. The 
number of tablets or capsules contained in each vial was 
then entered into the experimenter's records. 
During those phases in which unit-dose packaging 
was employed, counts were made by noting the number of tab-
lets or capsules in each cell for each day. The total 
count remaining in the subject's supply was obtained by 
multiplying the number of intact cells remaining in that 
prescription by the number of capsules or tablets in each 
cell and adding the number in partial cells and those 
remaining in the vial, if any. 
Reliability assessment. The reliability of the 
experimenter's vial counts was assessed once in each phase 
by an independent observer. Upon their arrival at the 
subject's home, the experimenter and the observer silently 
counted the contents of each vial or package, and each 
count was recorded separately. The smaller number was 
to be divided by the larger and multiplj_ed by 100 to yield 
a reliability estimate. In no case was there any 
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discrepancy between the experimenter's and the observer's 
counts; reliability was always 100%. 
Description of treatment phases. The first count 
for those subjects agreeing to participate was made at the 
end of the initial interview and thereafter according to the 
schedules in Appendix A. The experimenter would arrive, 
unannounced, at the subject's residence and ask the sub-
ject to bring him all the vials containing medications 
prescribed by the referring clinic. The experimenter would 
silently count the contents of each vial separately, using 
the counting tray described. The experimenter then thanked 
the subject for his or her cooperation and left without 
further comment. The baseline lengths were as follows: Sub-
ject l, 30 days; Subject 2, 19 days; Subject 3, 34 days; 
Subject 4, 29 days; Subject 5, 29 days; Subject 6, 27 days. 
Variations in the baseline lengths were due to three fac-
tors: (a) the availability of the medications for packaging, 
(b) the time required to unit-dose package each prescription, 
and (c) in the case of Subject 2, the availability of the 
subject to begin the baseline counts. 
On the first day of the first treatment phase (BC), 
the experimenter packaged the subject's medications in 
the unit-dose form described and delivered them to the sub-
ject's residence. At that time the experimenter handed the 
subject a sample unit-dose package and gave the instructions 
in Appendix D concerning the correct use of the system. 
During this phase, contingent upon either an improvement 
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in compliance or the maintenance of perfect compliance, 
social reinforcement was administered by the experimenter. 
This took the following forms: smiles, handshakes, and 
statements of approval. Such statements consisted of 
such expressions as "You're much better this time; you've 
taken everything accurately yesterday and today. Keep it 
up. You're doing fine." In the cases where perfect com-
pliance was being maintained, verbal reinforcement took the 
form "You've been perfect in taking your pills all week. 
Not a single mistake. Keep up the good work." If the sub-
ject's compliance rate was deteriorating, the experimenter 
made no comment after the counts, except for the customary 
statement of appreciation of the subject's continued 
participation in the study. The duration of this phase was 
as follows: Subject 1, 12 days; Subject 2, 12 days; Subject 
3, 12 days; Subject 4, 16 days; Subject 5, 9 days; Sub-
ject 6, 15 days. Differences in these figures reflect vari-
ability in the subjects' availability for the administration 
of social reinforcement. 
During the second treatment phase, the subjects' 
medications were unit-dose packaged, but no social rein-
forcement was administered. The subject's supply was 
~ilently counted using the method described; the experimenter 
then thanked the subject for cooperating and left. For 
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Subjects 1, 2, and 3, this phase lasted 9 days; for Sub-
jects 4, 5, and 6, it lasted 11, 15, and 12 days, respec-
tively. Differences in these figures were the result of 
the factor described above. 
For Subjects 1, 2, and 3, an additional treatment 
phase was added at this point, combining unit-dose pack-
aging and social reinforcement (BC). This phase was 
identical to the first treatment phase. Its duration was 
12, 9 and 9 days for Subjects 1, 2, and 3, respectively. 
The phase was longer for Subject 1, because the perfo~mance 
of that subject had not stabilized by Day 9. 
The reversal phase (A) was identical to the base-
line phase. For Subjects 1, 2, and 3, reversal lasted 9 
days; for Subjects 4 and 5, its duration was 10 days; for 
Subject 6, it lasted 19 days, including a 10 day interruption. 
Termination. Upon the last day of the reversal 
phase, the subject was informed that the procedures were com-
pleted. He or she was told the purpose of the study, his 
or her individual performance under each condition, and 
the general, preliminary results of the study as a whole. 
His or her comments were solicited, and all questions 
were fully answered. At this point the subject was asked 
whether he or she wished his or her baseline,treatment, and 
reversal phase data made available to the appropriate staff 
members at the referring clinic. Four of the six subjects 
gave that permission. 
RESULTS 
Table 2 and Figures 7 through 14 show the results 
obtained. To obtain a figure representing the percentage of 
the prescribed regimen which was consumed by the subject in 
each three-day period, each Data Count was subtracted from 
the previous one and divided by the number of tablets or 
capsules prescribed for that period. This figure was then 
multiplied by 100. On Table 2, the range for each experi-
mental period is the highest and lowest compliance figures 
obtained during that time. The average discrepancy is the 
sum of the absolute values of the differences between the 
compliance figures obtained and 100% divided by the number 
of compliance values obtained during that experimental 
period. 
Subject One. The compliance figures plotted on 
Figure 7 on Days 24 and 27 for Artane show undermedication 
due to the lack of a sufficient supply of this drug. When 
this subject's prescriptions were last refilled, she had 
enough to last until the next scheduled refill, but over-
medication early in the first weeks after the prescriptions 
were refilled depleted her supply, making later undermedica-
tion inevitable. Further, the overmedication with Prolixin 




SUMMARY OF RESULTS 
Treatment Phase 
Baseline One Two Reversal ----~~--
Su~:>j ect One 
Prolixin 
Range 100-133 100 100 88-150 
Average 
Discrepancy 3.3 0 0 20.7 
Artane 
Range 44-122 100-111 100 100-122 
Average 
Discrepancy 12.2 2.2 0 7.3 
Subject T\VO 
Elavil 
Range 67-125 100 100 50-75 
Average 
Discrepancy 14.9 0 0 41.7 
Tindal 
Range 60-107 100 100 
Average 
Discrepancy 17.6 0 0 
Subject Three 
Tindal 
Range 0-94 100 36-100 0-150 
Average 
Discrepancy 59.1 0 16.0 64.5 
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Table 2. Continued. 
Treatment Phase 
Baseline One Two Three Reversal 
Subject Four 
Valium 
Range 0-250 100-117 100-117 83-125 138-183 
Average 
Discrepancy 67.0 4.3 5.7 10.5 65.3 
Elavil 
Range 67-233 100 100 100 100-150 
Average 
Discrepancy 28.7 0 0 0 16.7 
Permarin 
Range 100-250 100 100 100 100-125 
Average 
Discrepancy 30.0 0 0 0 8.3 
Dilantin 
Range 100-150 100 100 100 100-150 
Average 
Discrepancy 6.7 0 0 0 16.7 
Subject Five 
Haldo1 
Range 31-73 25-100 27-85 42-75 42-58 
Average 
Discrepancy 50.2 39.5 48.7 44.3 47.3 
Artane 
Range 50-138 33-100 33-100 67-100 17-100 
Average 
Discrepancy 30.0 37.5 28.0 16.7 33.3 
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Table 2. Continued. 
Treatment Phase 
---~-~--
Baseline One Two Three Reversal 
Subject Six 
Librium 
Range 0-267 100-144 0-113 100-111 100-138 
Average 
Discrepancy 59.2 16 56.5 3.7 16.3 
Elavil 
Range 56-178 111-133 67-156 100-111 67.100 
Average 
Discrepancy 24.9 27.5 33.0 3.7 11.0 
Dalmane 
Range 33-117 117-133 67-200 100-133 75-117 
Average 
Discrepancy 18.2 25.0 50.0 11.0 14.0 
Vitamin B Complex 
Range 50-200 100-133 33-100 100-133 100 
Average 
Discrepancy 31.8 16.5 22.3 22.0 0 
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FIG.OR.E 7 ~ Percentage of Prescribed Regimen Consumed by 
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Subject 4 (Valium and Elavil) During Baseline, 
Treatment, and Reversal Phases. 
FIGURE 11. Percentage of Prescribed Regimen Consumed by 
Subject 4 (Dilantin and Premarin) During 
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FIGURE 13. Percentage of Prescribed Regimen Consumed by 
Subject 6 (Librium and Elavil) During Baseline, 
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FIGURE 14. Percentage of Prescribed Regimen Consumed by 
Subject 6 (Dalmane and Vitamin B Complex) 
During Baseline, Treatment, and Reversal Phases. 
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same time as the undermedication with Artane. These two 
trends -- the overmedication-undermedication cycle and the 
overmedication with one drug when the supply of another has 
been exhausted -- are seen in each subject for whom over-
medication is apparent (Subjects 1, 4, and 6). The 111% 
figure obtained on Day 44 resulted from the subject's taking 
one Artane tablet from a supply of unpackaged tablets. 
Subject Two. On Day 13 the strength of this sub-
ject's daily Elavil dose was increased from 100 mg. to 150 
mg., requiring the taking of one more 50 mg. tablet daily. 
Between Days 18 and 27, this subject was taking exactly two-
thirds of the prescribed dose. On Day 47 the prescribing 
physician discontinued this subject's Tindal prescription. 
Subject Three. Between Days 9 and 16 Subject 3 made 
an unannounced departure from the area, and no counts could 
be made. The later baseline compliance figures show under-
compliance due to an exhausted supply, but it is possible that 
not enough Tindal was dispensed at the previous refill to last 
until the next scheduled refill. Between Days 42 and 45, 
Subject 3 made a change of residence which corresponded with 
a decrease in his compliance rate from 100% to 36%. On Day 
57 Subject 3 exhausted his supply of Tindal but could not 
obtain a refill until Day 64 due to the fact that he had lost 
his Medj.-Cal Card. No compliance figures are plotted for 
this period since this undercompliance was due, apparently, 
to factors beyond the subject's control. 
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Subject Four. The overrnedication-undermedication 
cycle and the overmedication with one drug in conjunction 
with undermedication with another are clearly seen in the 
baseline data. The 117% figure plotted on Day 33 is the re-
sult of the subject's taking the only Valium tablet which 
was not unit-dose packaged. The 117% figure obtained on 
Day 48 is the result of the subject's taking one Valium 
tablet from the following day's package. This did not result 
in undercompliance on this following day, because a refill was 
obtained then. The 125% figure on Day 60 and the 83% figure 
on Day 63 reflects the subject's taking one Valium tablet 
three hours prior to her usual bedtime on Day 60. 
Subject Fiye. This subject's baseline was shorter 
than the other subjects' baselines because he was not 
available to begin until a later date. Treatment was 
begun on Day 19 since that corresponded to the scheduled date 
for initiating treatment for Subject 6 who was living in the 
same household. To avoid the problem of the two being in 
different phases throughout the experimental procedures, 
treatment was begun on the same day. 
Subject Stx. The overmedication-undermedication cycle 
and the overmedication with one drug in conjunction with 
undermedication with another are in evidence both during the 
baseline and treatment phases. On Day 29 prescription refills 
were obtained, but apparently during that evening some of the 
Librium was stolen during a party. The remaining contents of 
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the vial were found scattered over the floor of the closet 
where the drugs were stored. Several capsules were found on 
the floor during the next few days, and a stable count could 
not be obtained until Day 34. No compliance figures were 
plotted for Librium between Days 52 and 57, since the count 
obtained on Day 34 allowed the subject only enough Librium to 
last until Day 52. 
DISCUSSION 
The results obtained suggest that the use of unit-
dose packaging can improve compliance with medication 
regimens. In four of the six subjects (Subjects l - 4) 
the introduction of the treatment procedures resulted in 
an immediate and sustained improvement, and the termina-
tion of those procedures in a deterioration in performance. 
In another subject (Subject 6) the introduction of the 
treatment procedures resulted in an initial improvement 
in compliance with two drugs and an eventual improvement 
in all four, and in the last subject (Subject 5) an 
initial improvement was found with one drug and a gradual 
improvement was found with the other. 
The effects of contingent verbal reinforcement are 
not clear. The withdrawal of this variable in the second 
treatment phase did not result in a deterioration in per-
formance. In those cases in which some deterioration was 
found in this phase other possible causes can be identified. 
The change of residence by Subject 3 occurred at the same 
time as the deterioration in performance at the onset of 
the second treatment phase. That deterioration was not 
sustained and occurred only during that limited time. Sub-
ject·6 exhausted her supply of Librium during that phase, and, 
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predictably, overmedicated with other drugs until refills 
could be obtained. It is not felt that the withdrawal of 
contingent verbal reinforcement was the cause of that de-
terioration. Further study will be required to identify 
the effects of contingent verbal reinforcement upon medi-
cation non-compliance. 
There was concern that the experimental interven-
tion would have a disruptive effect on the subject's ac-
curacy of self-medication, resulting in dangerously low 
compliance rates. That concern prompted the selection of 
unit-dose packaging combined with verbal reinforcement as 
the first treatment phase. The effects of verbal rein-
forcement alone might have been more clear had that phase 
not been preceded by one combining that variable with unit-
dose packaging. The concern about the possible disruptive 
effect of intervention was not warranted, given the re-
sults obtained. It is suggested that future research in 
this area employ designs which assess the effects of each 
of the two variables alone prior to assessing their combined 
effects. 
The results obtained suggest that the improvement 
in performance observed during the treatment phases was not 
due to a novelty effect. None of the subjects showed the 
steady deterioration in performance, either within each 
treatment phase or during the entire treatment intervention, 
that would have been expected had a novelty effect been 
in operation. The deterioration in the performance of Sub-
ject 4 observed during the second treatment phase was not 
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reversed by the reinstatement of verbal reinforcement. The 
performance of Subject 5 showed little change across con-
ditions with cne drug and a gradual improvement with the 
other. Neither of these results would be explained by a 
novelty effect. The improvement in the performance of 
Subject 6 during the third treatment phase was due to the 
subject's no longer being as free to circumvent the experi-
mental procedures. 
In the writing of the informed consent forms, the 
experimenter closely followed the Ethical Standards of the 
American Psychological Association. By informing the sub-
ject of the possible benefits in participating in the study, 
a demand characteristic may have been created which could 
have resulted in the improved performances in the treatment 
conditions. It is suggested that in further research the 
instructions to the subjects and the consent forms be 
written in such a way as to minimize the possibility of a 
demand characteristic. 
Subject 5 was aware of the danger of drinking 
alcoholic beverages while taking psychotropic drugs. Con-
sequently since his customary activity on Fridays, 
Saturdays, and Sundays was to drink with his friends, his 
compliance rates were often lower during the weekends than 
during the rest of the week. The treatment procedures em-
ployed did not substantially alter this tendency. 
A simpler regimen would likely have increased com-
pliance in Subject 5, especially in conjunction with the 
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treatment procedures in the present study. It was observed 
by the experimenter that the morning and evening doses were 
taken with somewhat more aecuracy than the two mid-day doses. 
The results for Artane on Figure 12 may be compared with 
those for Haldol to see the better compliance rates which 
may be found with a twice daily schedule than with a four 
times daily schedule. The results in the present study, 
then, tend to support Blackwell's (1972) position that a 
simple regimen is preferred over a more complex one in view 
of the better compliance with the former. 
A factor which limited the effectiveness of the pro-
cedures was the availability to several of the subjects of 
unpackaged tablets or capsules. These remained after the 
experimenter had unit-dose packaged each subject's monthly 
or semi-monthly supply. For example, if the subject had 45 
tablets of one medication and 50 of another, both of which 
he or she was directed to take three each day, then the ex-
perimenter packaged 45 of each, or exactly 15 days supply, 
leaving 5 tablets of the first medication unpackaged. On 
several occasions, the subject with non-packaged medications 
used this extra supply, even when requested by the experi-
menter not to do so. Examples of this are seen on Day 45 
on Subject 1 (Artane), Day 33 of Subject 4 (Valium), and 
on at least eight occasions of Subject 6 (Elavil, Dalmane 
and Vitamin B). 
In the case of this last subject, it was apparent 
that the daily unit-dose cards were used with some regularity, 
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but the subject took doses from the unpackaged supplies when 
she felt she needed them. Compliance would not have been 
perfect during this time, but may well have been better 
had this extra supply not been available. Indeed, when this 
subject's prescriptions were refilled on Day 55, the experi-
menter packaged all of the subject's supplies of each drug, 
and the results in the third treatment phase show dramatic 
improvement over the first two treatment phases; no extra 
unpackaged supplies were then available. It is suggested, 
in view of this problem, that all of each subject's supply 
of every drug be unit-dose packaged in future applications 
of these techniques. 
The baseline figures indicate that the critical 
point in the taking of the more abused medications -- Lib~ 
rium, Valiwn, Elavil, and Dalmane -- is immediately after 
they are dispensed. It is at this point that, without 
intervention, the compliance rates show the dramatic in-
creases. Overcompliance at this time necessarily indicates 
undercompliance later as was mentioned previously, since 
only enough is dispensed to last until the next fixed ap-
pointrnent for a prescription refill. Subjects whose supply 
of a medication is exhausted often attempt to compensate 
by overcompliance with other medications. These tendencies 
can be seen in the baseline figures for Subjects 1, 4, and 
6, but after the medications were unit-dose packaged, ex-
treme overcompliance after dispensing did not occur, and 
undercompliance due to an exhausted supply occurred only 
once (Subject 6). 
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The function of the unit-dose packaging system 
was to facilitate the self-monitoring of medication~taking 
behavior. The effectiveness of behavioral self-control 
techniques often depends directly upon the degree to which 
the subject is continuously made aware of the frequency 
with which he or she is engaging in the target behavior 
and the magnitude of the discrepancy between his or her 
present level of performance and the target level of per-
formance. The unit-dose packaging system provided the 
subject with a definition of the target behavior for each 
day -- to take a certain number of certain tablets or 
capsules at certain times -- and allowed the immediate 
knowledge of the degree to which the daily regimen was being 
followed. 
During the debriefing, the subjects reactions to the 
procedures were solicited. Subject 1 stated that during 
the treatment phase she knew she was self-medicating with 
more accuracy and felt better about herself as a result. 
Her relation to the unit-dose packaging was strongly 
positive. Subjects 2 and 3 had no comments, either posi-
tive or negative. Subject 4 was very enthusiastic about 
the packaging system and her performance during its employ-
ment. She voiced disappointment that it could not be con-
tinued indefinitely. Subjects 5 and 6 did not like the 
intervention. They were glad that their medications 
would no longer be packaged in the unit-dose form, and that 
their supplies would no longer be counted. Subject 6 
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regarded this latter aspect of the intervention to be an 
affront. 
Atterr._pts to deal with the problem of medication non-
compliance in outpatient populations have been limited to 
simple, short-term, nonpsychiatric regimens. The present 
study suggests a way to produce and maintain compliance with 
complex, long-term regimens in psychiatric outpatients. 
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APPENDIX A 
SCHEDULES OF COUNTS AND DATA COUNTS 
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SUBJECT ONE 
Data Data Data 
Count Count Count Count Count Count 
Day Times Times Day Times Times Day Times Times 
0 4:00 23 8:30 45 6:30 
1 s 24 5:30 46 
2 25 47 9:00 
3 5:00 26 7:00 48 
4 27 6:30 49 
5 28 50 9:30 s 
6 7:00 s 29 7:00(SF) 51 
7 30 9:00 52 4:00 
8 8:00 31 53 6:00 
9 6:30 32 9:00 54 
10 33 55 9:30(SF) 
11 1:30 34 56 
12 35 7:00 s 57 
13 5:30(SP) 36 58 
14 37 s 59 8:00 
15 7:30 38 7:30 60 12:30 
16 ll:OOa.m. 39 61 
17 40 9:00 62 
18 5:30 41 9:30 63 8:30(SP) 
19 42 64 
20 43 65 9:00 
21 6:00 8:00 44 8:30 
22 
NOTE: A Data Count Time designated by SP in parentheses 
had been scheduled for the previous day, but could 
not be made then due to the subject's inavailability. 
A Data Count designated by SF in parentheses had been 
scheduled for the following day but was made on the 
day indicated due to a lengthy absence of the subject 
or a phase change. An S indicates that a count had 
been scheduled but was not made due to the subject's 
inavailability. 
All counts were made in the afternoon or in the evening 




Data Data Data 
Count Count Count Count Count Count 
Day Times Times Day Times Times Day Times Times 
0 2:00 22 43 
1 s 23 s 44 3:00 
2 24 4:00 45 12:00 
3 5:00 25 46 
4 26 s 47 4:00 
5 27 1:30 48 
6 4:00 6:30 28 49 
7 29 8:00 50 
8 7:30 30 12:30 51 8:00(SP) 
9 s 31 52 s 
10 32 7:00 53 8:30 
11 s 33 54 
12 8:30 34 55 8:00 
13 35 2:00 56 
14 36 57 9:00(SP) 
15 3:30 37 6:30 58 
16 1:00 38 1:30 59 1:30 
17 39 60 8:30 
18 6:00 40 8:00 61 
19 41 5:00 62 
20 42 63 7:00(SP) 
21 4:30 s 
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SUBJECT THREE 
Data Data Data 
Count Count Count Count Count Count 
Day Times Tj_mes Day Times Times Day Times Times 
0 4:30 25 50 s 
1 s 26 5:30 51 2:30 
2 27 7:00 52 
3 5:00 28 6:30 53 9:00 
4 29 54 8:00 
5 30 8:00 55 
6 4:30 s 31 56 
7 32 57 8:30 
8 6:00 33 4:30 s 58 9:00 
9 9:30 34 59 
10 35 4:30 60 s 
11 s 36 2:00 61 
12 s 37 62 
13 38 9:00 63 
14 39 7:30 64 3:30(SP) 
15 40 65 
16 2:00(SP) 41 66 8:00 
17 42 2:00 67 4:00 
18 6:00 43 5:00 68 
19 44 69 9:00 
20 45 12:30 70 6:30 
21 3:00 9:00 46 71 
22 47 72 s 
23 1:30 48 6:00 s 73 7:00 
24 4:30 49 
54 
SUBJECT FOUR 
Data Data Data 
Count Count Count Count Count Count 
Day Times Times Day Times Times Day Times Times 
~--~-~-~-. 
0 3:30 25 49 
1 s 26 6:30 50 
2 27 51 3:00 
3 4:30 28 7:00(SP) 52 
4 29 53 8:00 
5 30 8:30 54 4:00 
6 3:00 s 31 7:30 55 
7 32 56 s 
8 7:30 33 4:00 57 9:00 
9 34 58 
10 ll:OO(SP) 35 59 
11 s 36 6:00 s 60 4:30 
12 5:00 37 61 8:00 
13 38 .2:00 62 
14 39 3:30 63 8:00 
15 2:00 40 64 
16 s 41 5:00 65 
17 42 9:00 66 8:30 s 
18 5~30 43 67 
19 44 68 8:30 
20 45 1:00 69 6:00 
21 1:30 8:00 46 8:00 70 
22 47 71 s 




Data Data Data 
Count Count Count Count Count Count 
Day Times Times Day Times Times Day Times Times 
----~--~--~ 
0 8:00 20 4:00 40 9:00 s 
1 2:30 21 41 
2 22 6:30 42 9:00 
3 23 43 9:00 
4 8:30(SP) 24 44 
5 25 8:30 s 45 9:00 
6 7:30 2:00 26 46 9:00 
7 27 .7:00 47 
8 4:00 28 7:00 48 7:30 
9 5:00 29 49 9:30 
10 30 12:30 50 
11 6:30 31 9:00 51 
12 8:00 32 52 9:30 
13 33 2:30 53 
14 34 9:30 54 9:00 
15 7:30 35 55 6:00 
16 5:00 36 4:00 56 
17 37 4:00 57 
18 38 58 7:30 
19 5:30(SP) 39 
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SUBJECT SIX 
Data Data Data 
Count Count Count Count Count Count 
Day Times Times Day Times Times Day Times Times 
0 8:00 25 50 
1 s 26 6:30 51 7:30 
2 27 8:00 52 4:00 
3 8:30 28 53 
4 29 54 
5 30 7:30 55 9:00 s 
6 9:30 s 31 5:00 56 
7 32 57 9:00 
8 1:30 33 58 9:00 
9 6:00 34 S:OO(SP) 59 
10 35 4:00 60 4:30 
11 s 36 61 9:00 
12 9:00 37 6:30 62 
13 38 63 2:00 
14 39 64 9:30 
15 8:00 40 7:30 s 65 
16 2:30 41 66 
17 42 7:00 67 9:30 
18 43 7:00 68 
19 8:30(SP) 44 69 9:30 
20 45 12:30 70 6:00 
21 7:30 2:00 46 9:00 71 
22 47 72 
23 4:00 48 73 7:30 
24 5:00 49 8:30 
APPENDIX B 
INFORMED CONSENT FORMS 
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SAN JOAQUIN COUNTY MENTAL HEALTH SERVICES 
MEDICP.TION COMPLIANCE RESEARCH - WEST IRVIN 
INFORMED CONSENT FORM 
58 
I understand that the observation and treatment 
involving medication taking provided by West Irvin and his 
research associates are experimental procedures. I under-
stand that the purpose of the study is to test a new way 
of packaging and administering medications so that people 
will take them more accurately and that the only known pos-
sible risk to me by my participation is that I might be 
less accurate in taking my medications than I am now. 
It is my understanding that there will be four parts 
to this study, each lasting about two weeks. The first will 
involve only the counting every few days of the capsules 
or tablets left in each of the bottles in which I normally 
receive my medications. The second part will be an experi-
mental phase, during which I will receive my medications 
in a new form of packaging, which I have been shown and I 
will get feedback about the accuracy with which I take them. 
During the third part, also an experimental phase, I will 
still get my medications in the new package, but I will not 
receive any feedback about my accuracy in taking them. The 
fourth part will be just like the first one; my medications 
will be in the regular bottles just like they usually are now, 
and they will be counted every few days. 
59 
I understand that any difference in success or fail-
ure between myself and other people participating in this 
project does not signify anything about my intelligence or 
character. I understand that I am free to ask any questions 
I may have about the study and that I may drop out at any 
time. 
Your Signature ________________ __ 
Please Print Your Name -------------------
Date ------------------
60 
CONSENT FOR PARTICIPATION IN MEDICATION PACKAGING 
PROGRAM 
I give West Irvin permission to take the medications 
prescribed for my use by the staff of the San Joaquin 
County Mental Health Services, to the School of Pharmacy 
at the University of the Pacific. I also give him permis-
sian to package them in the Medi-DosejMedi-Cup packaging 
system, which I have been shown. He will then return them 
to me. 
I understand that the medications from several 
prescriptions may be packaged together in each of the cups 
in the Medi-DosejMedi-Cup system. I understand that this 





PRELIMINARY INSTRUCTIONS TO SUBJECTS 
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I'm working with the San Joaquin County Mental 
Health Service and the University of the Pacific to test 
a new way of packaging and administering medications. Mrs. 
Porter at the Clinic suggested that you might be interested 
in helping out with this project. Let me tell you a little 
about it and see what you think. What will happen is I'll 
be stopping by every couple of days for a few minutes to 
count the number of pills you have left in each of your 
prescriptions. After a couple of weeks, I'd like you to 
try out a new kind of pill package. It will look like 
this. (Show sample) After four weeks using the new pack-
age, we'll switch back to tne way you get your medications 
now. That way we can compare how you like the old way 
with the new way. That's all. It will take a few minutes 
of your time every couple of days for about ten weeks. It 
won't cost you anything. Your medications will all be the 
san1e as they usually are. Do you have any questions? Would 
you like to help? 
63 
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This is the new way of getting your medicine that 
I showed you when I first asked for your help. This is 
how it works. [The experimenter shows the subject a sample 
unit-dose package.] You see, each of these cards holds 
all the medicine you're supposed to take in one day. Each 
dose is set in the card by itself, and when you need to 
take one, you just take it out like this. [The experi-
menter removes one dose from the sample package.] Just 
pull up the corner of the plastic like this, catch the 
pills as the plastic opens up, and take them like you 
always do. Now you try it. [The subject removes a dose 
from the sample package.] Good, that's the way. Try it 
one more t i.me. [The subject removes another dose,) OK. 
you've got the idea. Now, there'a a mark on the card next 
to each dose that tells you when you should take it. For 
example, this one should be taken on Wednesday, July 2 in 
the morning; this one should be taken on Wednesday, July 2 
at noon; these two should be taken on Wednesday, July 2 at 
bedtime. [The experimenter points to the dose, the day of 
the week, the date, and the time as he mentions each.] 
Now, which tablets should you take on Friday, July 4 at 
noon? Good. Now which ones should you take on Saturday, 
July 5 at bedtime? You've got the idea. [If the subject 
makes any errors, the experimenter repeats the instructions 
until the subject makes no errors.] Do you have any questions? 
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I'll be back within a couple of days to see how you're 
doing. Just take your pills like you always do. The only 
difference is that they will be in this new package. -----------
